These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38599653)

  • 1. Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.
    Ørbo HS; Bjørlykke KH; Sexton J; Jyssum I; Tveter AT; Christensen IE; Mjaaland S; Kvien TK; Grødeland G; Kro GB; Jahnsen J; Haavardsholm EA; Munthe LA; Provan SA; Vaage JT; Goll GL; Jørgensen KK; Syversen SW
    RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam.
    Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R
    Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of the intranasal spray SARS-CoV-2 vaccine dNS1-RBD: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu F; Huang S; Liu X; Chen Q; Zhuang C; Zhao H; Han J; Jaen AM; Do TH; Peter JG; Dorado AG; Tirador LS; Zabat GMA; Villalobos REM; Gueco GP; Botha LLG; Iglesias Pertuz SP; Tan J; Zhu K; Quan J; Lin H; Huang Y; Jia J; Chu X; Chen J; Chen Y; Zhang T; Su Y; Li C; Ye X; Wu T; Zhang J; Xia N;
    Lancet Respir Med; 2023 Dec; 11(12):1075-1088. PubMed ID: 37979588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody prevalence after three or more COVID-19 vaccine doses in individuals who are immunosuppressed in the UK: a cross-sectional study from MELODY.
    Pearce FA; Lim SH; Bythell M; Lanyon P; Hogg R; Taylor A; Powter G; Cooke GS; Ward H; Chilcot J; Thomas H; Mumford L; McAdoo SP; Pettigrew GJ; Lightstone L; Willicombe M
    Lancet Rheumatol; 2023 Aug; 5(8):e461-e473. PubMed ID: 38251578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
    Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N
    Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.
    Madhi SA; Koen AL; Izu A; Fairlie L; Cutland CL; Baillie V; Padayachee SD; Dheda K; Barnabas SL; Bhorat QE; Briner C; Aley PK; Bhikha S; Hermanus T; Horne E; Jose A; Kgagudi P; Lambe T; Masenya M; Masilela M; Mkhize N; Moultrie A; Mukendi CK; Moyo-Gwete T; Nana AJ; Nzimande A; Patel F; Rhead S; Taoushanis C; Thombrayil A; van Eck S; Voysey M; Villafana TL; Vekemans J; Gilbert SC; Pollard AJ; Moore PL; Kwatra G;
    Lancet HIV; 2021 Sep; 8(9):e568-e580. PubMed ID: 34416193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study.
    Ørbo HS; de Matos Kasahara T; Wolf AS; Bjørlykke KH; Sexton J; Jyssum I; Tveter AT; Solum G; Kjønstad IF; Bhandari S; Christensen IE; Kvien TK; Lind A; Kared H; Jahnsen J; Haavardsholm EA; Munthe LA; Provan SA; Vaage JT; Mjaaland S; Syversen SW; Jørgensen KK; Grødeland G; Goll GL
    Lancet Reg Health Eur; 2025 Jan; 48():101121. PubMed ID: 39624496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adult vaccination in India: A rapid review of current status & implementation challenges.
    Bhattacharyya A; Shahabuddin SM
    Indian J Med Res; 2024 Sep&Oct; 160(3&4):279-292. PubMed ID: 39632644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study.
    Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H
    Front Immunol; 2024; 15():1448408. PubMed ID: 39606247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ethnic differences in cellular and humoral immune responses to SARS-CoV-2 vaccination in UK healthcare workers: a cross-sectional analysis.
    Martin CA; Nazareth J; Jarkhi A; Pan D; Das M; Logan N; Scott S; Bryant L; Abeywickrama N; Adeoye O; Ahmed A; Asif A; Bandi S; George N; Gohar M; Gray LJ; Kaszuba R; Mangwani J; Martin M; Moorthy A; Renals V; Teece L; Vail D; Khunti K; Moss P; Tattersall A; Hallis B; Otter AD; Rowe C; Willett BJ; Haldar P; Cooper A; Pareek M
    EClinicalMedicine; 2023 Apr; 58():101926. PubMed ID: 37034357
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Goswami J; Cardona JF; Hsu DC; Simorellis AK; Wilson L; Dhar R; Tomassini JE; Wang X; Kapoor A; Collins A; Righi V; Lan L; Du J; Zhou H; Stoszek SK; Shaw CA; Reuter C; Wilson E; Miller JM; Das R;
    Lancet Infect Dis; 2024 Nov; ():. PubMed ID: 39608389
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine preventable diseases and vaccination coverage in Aboriginal and Torres Strait Islander people, Australia 2006-2010.
    Naidu L; Chiu C; Habig A; Lowbridge C; Jayasinghe S; Wang H; McIntyre P; Menzies R
    Commun Dis Intell Q Rep; 2013 Dec; 37 Suppl():S1-95. PubMed ID: 24410428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT.
    Coulton S; Nizalova O; Pellatt-Higgins T; Stevens A; Hendrie N; Marchand C; Vass R; Deluca P; Drummond C; Ferguson J; Waller G; Newbury-Birch D
    Public Health Res (Southampt); 2023 Mar; 11(3):1-77. PubMed ID: 37254608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uptake, effectiveness and safety of COVID-19 vaccines in individuals at clinical risk due to immunosuppressive drug therapy or transplantation procedures: a population-based cohort study in England.
    Chen DT; Copland E; Hirst JA; Mi E; Dixon S; Coupland C; Hippisley-Cox J
    BMC Med; 2024 Jun; 22(1):237. PubMed ID: 38858672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years.
    Feldstein LR; Britton A; Grant L; Wiegand R; Ruffin J; Babu TM; Briggs Hagen M; Burgess JL; Caban-Martinez AJ; Chu HY; Ellingson KD; Englund JA; Hegmann KT; Jeddy Z; Lauring AS; Lutrick K; Martin ET; Mathenge C; Meece J; Midgley CM; Monto AS; Newes-Adeyi G; Odame-Bamfo L; Olsho LEW; Phillips AL; Rai RP; Saydah S; Smith N; Steinhardt L; Tyner H; Vandermeer M; Vaughan M; Yoon SK; Gaglani M; Naleway AL
    JAMA; 2024 Feb; 331(5):408-416. PubMed ID: 38319331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal SARS-CoV-2 vaccine allocation using real-time attack-rate estimates in Rhode Island and Massachusetts.
    Tran TN; Wikle NB; Albert E; Inam H; Strong E; Brinda K; Leighow SM; Yang F; Hossain S; Pritchard JR; Chan P; Hanage WP; Hanks EM; Boni MF
    BMC Med; 2021 Jul; 19(1):162. PubMed ID: 34253200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 19. Ceftazidime with avibactam for treating severe aerobic Gram-negative bacterial infections: technology evaluation to inform a novel subscription-style payment model.
    Harnan S; Kearns B; Scope A; Schmitt L; Jankovic D; Hamilton J; Srivastava T; Hill H; Ku CC; Ren S; Rothery C; Bojke L; Sculpher M; Woods B
    Health Technol Assess; 2024 Oct; 28(73):1-230. PubMed ID: 39487661
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.